Michael Boettcher (M Böttcher)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 7

Top Topics

Transcatheter Aortic Valve Replacement

Placebo Controlled

Top Venues

Clinical pharmacokinetics

Clinical and translational science

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Boettcher, Bettina Nowotny, Robert Krausche, Corina Becker
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults. Clinical pharmacokinetics (2023)
Michael Boettcher, Bettina Nowotny, Robert Krausche, Corina Becker
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults. Clinical pharmacokinetics 62 (2) (2023)
Michael Boettcher, Bettina Nowotny, Robert Krausche, Corina Becker
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults. Clinical pharmacokinetics 62 (2) (2023)
Michael Boettcher, Bettina Nowotny, Robert Krausche, Corina Becker
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults. Clinical pharmacokinetics 62 (2) (2023)
Michael Boettcher, Bettina Nowotny, Robert Krausche, Corina Becker
Evaluation of the Influence of Sildenafil on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults. Clinical pharmacokinetics 62 (2) (2023)
Michael Boettcher, Gerd Mikus, Dietmar Trenk, Hans-Dirk Düngen, Frank Donath, Nikos Werner, Mahir Karakas, Nina Besche, Dominik Schulz-Burck, Mireille Gerrits, James Hung, Corina Becker
Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study. Clinical and translational science 15 (5) (2022)
Michael Boettcher, S Lentini, E R Arens, A Kaiser, D van der Mey, U Thuss, D Kubitza, G Wensing
First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. British journal of clinical pharmacology 84 (7) (2018)